The Mitochondrial Peptide
Mitochondrial Open Reading Frame of the 12S rRNA Type-c
MOTS-c is a mitochondria-derived peptide (MDP) encoded within the 12S rRNA gene of mitochondrial DNA. Discovered in 2015 by Dr. Changhan Lee at the University of Southern California, it represents a new class of signaling molecules that originate from mitochondrial DNA rather than nuclear DNA. MOTS-c is a key regulator of metabolic homeostasis and has been called an 'exercise mimetic' for its ability to reproduce some metabolic benefits of physical exercise.
MOTS-c regulates cellular metabolism by activating AMPK (the master metabolic switch), improving insulin sensitivity, and promoting fat oxidation. It acts as a retrograde signal from mitochondria to the nucleus, coordinating cellular energy balance.
Activates AMPK (AMP-activated protein kinase), the master switch for cellular energy metabolism, promoting glucose uptake and fatty acid oxidation.
Improves insulin sensitivity at the cellular level by enhancing glucose transporter (GLUT4) translocation to cell membranes.
Promotes fat oxidation and inhibits de novo lipogenesis, shifting cellular metabolism toward a leaner, more efficient energy utilization pattern.
Functions as a mitochondria-to-nucleus retrograde signal, representing a newly discovered communication pathway in cellular biology.
Activates AMPK and improves insulin sensitivity, supporting healthy glucose metabolism and potentially benefiting metabolic syndrome.
Reproduces some metabolic benefits of exercise at the cellular level, including improved glucose utilization and fat oxidation.
Supports mitochondrial health and function, the cellular organelles responsible for energy production that decline with age.
As a regulator of metabolic homeostasis and mitochondrial function, MOTS-c represents a novel approach to cellular aging intervention.
Discovery paper established MOTS-c as the first mitochondria-derived peptide that regulates insulin sensitivity and metabolic homeostasis through AMPK activation.
MOTS-c treatment prevented age-dependent and high-fat-diet-induced insulin resistance in mice, restoring metabolic function to youthful levels.
Circulating MOTS-c levels correlate with physical fitness and decline with age, suggesting it as both a biomarker and potential therapeutic target for age-related metabolic decline.
MOTS-c is a naturally occurring peptide produced by human mitochondria. As a relatively recently discovered compound (2015), long-term safety data is limited. Preclinical studies show favorable safety profiles with no significant adverse effects reported.
Research Status
MOTS-c was discovered in 2015 and has generated significant scientific excitement. Preclinical data is compelling, particularly for metabolic regulation. Human clinical data is in very early stages. Multiple research groups are actively investigating its therapeutic potential.
Regulatory Note
MOTS-c is not FDA-approved and is classified as a research compound. Its recent discovery means regulatory pathways have not been established. Available through select research-focused compounding pharmacies.